A detailed history of Hemington Wealth Management transactions in Abb Vie Inc. stock. As of the latest transaction made, Hemington Wealth Management holds 2,386 shares of ABBV stock, worth $424,731. This represents 0.13% of its overall portfolio holdings.

Number of Shares
2,386
Previous 2,491 4.22%
Holding current value
$424,731
Previous $427,000 13.82%
% of portfolio
0.13%
Previous 0.14%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$163.84 - $199.33 $17,203 - $20,929
-105 Reduced 4.22%
2,386 $486,000
Q2 2024

Aug 01, 2024

BUY
$154.79 - $180.76 $16,252 - $18,979
105 Added 4.4%
2,491 $427,000
Q1 2024

May 03, 2024

SELL
$159.82 - $182.1 $13,105 - $14,932
-82 Reduced 3.32%
2,386 $435,000
Q4 2023

Jan 26, 2024

BUY
$137.6 - $154.97 $30,272 - $34,093
220 Added 9.79%
2,468 $382,000
Q3 2023

Oct 20, 2023

SELL
$133.59 - $154.65 $26,718 - $30,930
-200 Reduced 8.17%
2,248 $335,000
Q2 2023

Aug 04, 2023

SELL
$132.51 - $164.9 $14,576 - $18,139
-110 Reduced 4.3%
2,448 $329,000
Q1 2023

May 05, 2023

BUY
$144.61 - $166.54 $5,350 - $6,161
37 Added 1.47%
2,558 $407,000
Q4 2022

Jan 30, 2023

BUY
$138.31 - $165.87 $13,692 - $16,421
99 Added 4.09%
2,521 $407,000
Q3 2022

Oct 31, 2022

SELL
$134.21 - $153.93 $805 - $923
-6 Reduced 0.25%
2,422 $325,000
Q2 2022

Jul 22, 2022

BUY
$137.62 - $174.96 $6,055 - $7,698
44 Added 1.85%
2,428 $372,000
Q1 2022

May 04, 2022

BUY
$131.98 - $163.75 $314,640 - $390,380
2,384 New
2,384 $387,000
Q4 2021

Jan 13, 2022

SELL
$107.43 - $135.93 $204,331 - $258,538
-1,902 Closed
0 $0
Q3 2021

Oct 06, 2021

BUY
$106.4 - $120.78 $4,043 - $4,589
38 Added 2.04%
1,902 $205,000
Q2 2021

Jul 09, 2021

BUY
$105.21 - $117.21 $196,111 - $218,479
1,864 New
1,864 $210,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $315B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Hemington Wealth Management Portfolio

Follow Hemington Wealth Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hemington Wealth Management, based on Form 13F filings with the SEC.

News

Stay updated on Hemington Wealth Management with notifications on news.